

Concept Paper

Not peer-reviewed version

Pathogenesis of Refractory SIBO and Oncological Risk in Hereditary Coproporphyrria: The Catalytic Role of HFE-Mediated Iron Overload

[Victor San Pedro Wandelmer](#)*

Posted Date: 28 February 2026

doi: 10.20944/preprints202602.1997.v1

Keywords: Hereditary Coproporphyrria; HFE mutation; small intestinal bacterial overgrowth; autonomic neuropathy; oxidative stress; non-transferrin-bound iron; cholangiocarcinoma



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a [Creative Commons CC BY 4.0 license](#), which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Concept Paper

Pathogenesis of Refractory SIBO and Oncological Risk in Hereditary Coproporphyrria: The Catalytic Role of HFE-Mediated Iron Overload

Víctor San Pedro Wandelmer

Independent Researcher, Spain; victor.sanpedro@gmail.com

Abstract

Background: The diagnosis of autonomic dysfunction underlying Hereditary Coproporphyrria (HCP) represents a major clinical challenge. Given the nonspecific and episodic nature of its crises, neurological and gastrointestinal symptoms are frequently misinterpreted and misdiagnosed as anxiety disorders or psychosomatic syndromes, severely delaying proper therapeutic management. Although HCP is characterized by the accumulation of porphyrin precursors, the high variability in tissue damage, ranging from refractory Small Intestinal Bacterial Overgrowth (SIBO) to inflammatory oncological processes (such as cholangiocarcinoma and cutaneous lymphomas), suggests the necessity of an external catalyst. We postulate that abnormal iron metabolism is the primary driver of this pathological progression. **Hypothesis:** Iron overload mediated by the HFE mutation, combined with low ferroxidase activity (ceruloplasmin), generates an excess of non-transferrin-bound iron (NTBI) in the ferrous state (Fe²⁺). Furthermore, the high demand for heme synthesis driven by elevated hemoglobin forces the defective CPOX enzymatic pathway, massively increasing the accumulation of isomer III precursors. Free Fe²⁺ then acts as an oxidizing agent, transforming the inert coproporphyrinogen III into highly reactive and toxic coproporphyrin III. **Mechanism:** The oxidation of these isomers triggers systemic oxidative stress. Locally, oxidized porphyrins induce autonomic neuropathy in the myenteric plexus, paralyzing gastrointestinal motility and promoting intractable SIBO. Systemically, the massive biliary excretion of these reactive compounds causes chronic chemical inflammation in the bile ducts, increasing the risk of cholangiocarcinoma. Concurrently, cutaneous deposition of oxidized porphyrins generates chronic antigenic stimulation in the dermis, potentially acting as a trigger for lymphoproliferative neoplasms, such as marginal zone B-cell lymphoma. **Clinical Relevance:** This model suggests that patients with overlapping HFE and CPOX mutations face both autonomic dysfunction (SIBO) and elevated oncological risk due to chronic inflammation. Early management through therapeutic phlebotomies to reduce hemoglobin-driven heme demand and halt Fe²⁺-mediated oxidation, alongside intestinal binders, could prevent both neurogastrointestinal damage and long-term malignant transformation.

Keywords: Hereditary Coproporphyrria; HFE mutation; small intestinal bacterial overgrowth; autonomic neuropathy; oxidative stress; non-transferrin-bound iron; cholangiocarcinoma

1. Introduction

Functional gastrointestinal disorders, most notably Irritable Bowel Syndrome (IBS) and Small Intestinal Bacterial Overgrowth (SIBO), are conventionally approached as localized functional impairments or isolated dysbiosis, primarily managed with dietary modifications and broad-spectrum antibiotics and the use of low-dose antidepressants (such as tricyclics) intended to modulate visceral hypersensitivity.

However, in a significant subset of patients, these syndromes are highly refractory and recurrent. This chronicity often points to a deeper underlying failure in gastrointestinal motility, specifically an autonomic neuropathy affecting the myenteric plexus.

When such persistent neurogastrointestinal symptoms present alongside systemic manifestations, investigating inborn errors of metabolism becomes **imperative**.

Hereditary Coproporphyrria (HCP), an autosomal dominant hepatic porphyria caused by a deficiency in the enzyme coproporphyrinogen oxidase (CPOX), is a prime candidate for such systemic disruption. The clinical presentation of HCP is notoriously elusive. Because its neurovisceral crises are episodic and lack specific routine biomarkers during latent phases, patients are frequently misdiagnosed for years with anxiety disorders, irritable bowel syndrome (IBS), or psychosomatic conditions.

This misdiagnosis leaves the true pathophysiology—the accumulation of neurotoxic porphyrin precursors—unchecked.

Despite the known genetic defect in CPOX, clinical penetrance in HCP is highly variable. While some patients remain largely asymptomatic, others develop severe autonomic dysfunction (leading to paralytic ileus and SIBO) or face severe long-term inflammatory consequences, including hepatobiliary malignancies (cholangiocarcinoma) and lymphoproliferative disorders. This marked phenotypic divergence suggests that the mere accumulation of coproporphyrinogen III is insufficient to cause severe tissue damage on its own; a **secondary, external catalyst** is required to trigger the toxic cascade.

This conceptual paper proposes a dual-hit mechanism where abnormal iron metabolism and chronic hypoxic stress act simultaneously as the drivers of precursor overproduction and the missing oxidative catalyst.

Specifically, we hypothesize that concurrent iron overload (driven by HFE gene mutations) combined with other conditions as could be intermittent hypoxia—such as that caused by sleep apnea—induces a state of secondary erythrocytosis.

The resulting **elevated hemoglobin creates a massive and continuous physiological demand for heme synthesis**. In the presence of a CPOX enzymatic bottleneck, this hyperstimulation forces a massive accumulation of inert coproporphyrinogen III.

Subsequently, compromised ferroxidase activity due to low ceruloplasmin levels fails to safely process the excess iron, creating a highly oxidative environment rich in non-transferrin-bound free ferrous iron (Fe²⁺).

This free Fe²⁺ then acts as the critical spark, oxidizing the massively accumulated inert porphyrinogens into highly reactive and toxic coproporphyrin III. It is this oxidized, phototoxic form that directly mediates myenteric nerve destruction (driving IBS/SIBO), chronic biliary inflammation, and cutaneous antigenic stimulation.

2. Clinical Observations and Pathophysiological Framework

2.1. Clinical Presentation and Family History

The hypothesis presented in this paper stems from the clinical observation of a striking familial cluster of metabolic, neurological, and oncological pathologies.

The proband, an adult male, presented with a long-standing history of severe, refractory SIBO and IBS-like symptoms, characterized by gastrointestinal dysmotility and suspected autonomic neuropathy. Conventional treatments, including multiple courses of broad-spectrum antibiotics and dietary restrictions, provided no sustained relief, indicating a structural or neurological deficit rather than a simple dysbiosis.

Beyond the enteric nervous system, the patient's autonomic and central nervous system involvement manifested as cardiac arrhythmias, palpitations, motor weakness in the extremities, and episodes of postural instability and dizziness. The proband also reported active neuropathic pain, notably a severe burning sensation across the chest, alongside significant arthralgia (joint pain) primarily affecting the hands and shoulders.

A critical clinical hallmark in the proband's history is a severe pharmacological intolerance. Multiple conventional medications—potentially including cytochrome P450-inducing drugs—

triggered paradoxical exacerbations of systemic symptoms, a characteristic sign of porphyrinogenic distress. Despite this, conventional treatments (such as broad-spectrum antibiotics and dietary restrictions) provided no sustained relief, indicating a structural or neurological deficit rather than simple dysbiosis.

Crucially, the patient's biochemical and genetic workup revealed a complex overlapping phenotype. The proband carries a genetic mutation in the HFE gene (predisposing to iron overload) and presents with persistently elevated hemoglobin levels.

Furthermore, the patient exhibits abnormally low levels of the ferroxidase enzyme, ceruloplasmin. Concurrently, the clinical picture aligns with the biochemical hallmarks of Hereditary Coproporphyrinuria (CPOX mutation), which causes a bottleneck in heme biosynthesis and the massive accumulation of coproporphyrinogen III.

The oncological history of the proband and his immediate family strongly supports a systemic inflammatory and oxidative mechanism driven by these overlapping metabolic errors.

The oncological history of the proband and his immediate family strongly supports a systemic inflammatory and oxidative mechanism driven by these overlapping metabolic errors.

The proband previously developed a primary cutaneous marginal zone B-cell lymphoma (PCMZL). Notably, standard clinical workups ruled out the classical infectious etiologies typically associated with this malignancy, such as *Borrelia burgdorferi* infection. In the absence of these typical exogenous triggers, this lymphoproliferative disorder strongly points toward an alternative source of chronic antigenic stimulation and localized inflammatory stress in the dermis: the continuous deposition and photo-activation of oxidized porphyrins.

More severely, there is a prominent family history of cholangiocarcinoma (affecting first- and second-degree male relatives, including the proband's father and uncle). This specific, aggressive hepatobiliary malignancy aligns perfectly with the chronic chemical trauma expected from the continuous biliary excretion of highly reactive, oxidized porphyrins.

2.2. The Diagnostic Gap

These clinical observations cannot be fully explained by either the HFE mutation or the CPOX mutation in isolation.

Standard medical paradigms treat iron overload and porphyria as separate entities. However, when these conditions co-occur, they create a perfect metabolic storm: a great demand for heme synthesis colliding with a broken enzymatic pathway, bathed in an excess of unchaperoned oxidative iron. This realization forms the basis of our proposed mechanistic framework.

3. Pathophysiological Mechanism: The Fenton Catalyst and Porphyrin Oxidation

The core of this hypothesis lies in the biochemical interaction between an accumulated, relatively inert metabolic precursor and an abundance of unchaperoned oxidative iron. I propose a three-step pathophysiological cascade that explains the transition from a latent genetic defect to a severe, multisystemic neurovisceral and oncological syndrome.

3.1. The Metabolic Bottleneck: Accumulation of Coproporphyrinogen III

In Hereditary Coproporphyrinuria, a partial deficiency of the enzyme coproporphyrinogen oxidase (CPOX) creates a bottleneck in the heme biosynthesis pathway.

During periods of high heme demand (such as erythropoietic stress driven by HFE-mediated iron loading), the pathway is hyperstimulated.

This forces a massive upstream accumulation of coproporphyrinogen III. Crucially, in its reduced state (the "-ogen" form), this hexahydroporphyrin is colorless, non-fluorescent, and relatively biologically inert.

It does not possess the rigid, planar structure required to cause severe mechanical or oxidative damage to tissues.

3.2. The Oxidative Spark: NTBI and Low Ceruloplasmin

For coproporphyrinogen III to become toxic, it must be oxidized into coproporphyrin III. This is where the overlapping iron dysregulation becomes the primary catalyst. The HFE gene mutation drives relentless intestinal iron absorption. Normally, excess iron is safely bound to transferrin or stored as ferritin. However, this safe transport relies heavily on ceruloplasmin, a crucial copper-containing ferroxidase that converts highly reactive ferrous iron (Fe²⁺) into the safer ferric state (Fe³⁺) so it can bind to transferrin.

In the proband's phenotype, low levels of ceruloplasmin lead to a catastrophic failure in this conversion process. The result is the generation of a significant pool of Non-Transferrin-Bound Iron (NTBI), specifically trapped in the highly reactive Fe²⁺ state. This free ferrous iron circulates systemically, penetrating tissues such as the liver, the enteric nervous system, and the dermis.

3.3. The Fenton Reaction and Tissue-Specific Damage

The presence of free Fe²⁺ alongside accumulated coproporphyrinogen III creates a volatile biochemical environment. Through the Fenton reaction (Fe²⁺+H₂O₂→Fe³⁺+OH+OH⁻), ferrous iron acts as a potent catalyst, generating highly damaging hydroxyl radicals. This localized oxidative stress rapidly and irreversibly oxidizes the accumulated inert coproporphyrinogen III into coproporphyrin III.

Unlike its flexible hexahydroporphyrin precursor, the Fenton-mediated oxidation strips six hydrogen atoms (6H⁺) and six electrons (6e⁻) from the meso bridges linking the pyrrole rings. This critical loss of hydrogen converts the flexible single bonds into a fully continuous system of alternating conjugated double bonds.

Consequently, the resulting oxidized coproporphyrin III is forced into a rigid, planar, highly conjugated tetrapyrrole ring. In this altered state, the molecule is profoundly reactive, phototoxic, and highly prone to aggregation (pi-stacking) within lipid-rich environments like neuronal sheaths. The continuous generation of this oxidized neurotoxin drives the multisystemic clinical presentation:

- **Enteric Neuropathy (SIBO/IBS):** Oxidized porphyrins exert direct oxidative and inflammatory damage on the unmyelinated neurons of the myenteric plexus. This chronic neurotoxicity induces profound autonomic dysfunction, paralyzing intestinal motility and providing the optimal stagnant environment for refractory Small Intestinal Bacterial Overgrowth.
- **Biliary Oncogenesis:** The liver attempts to clear these massive quantities of toxic porphyrins via biliary excretion. The rigid, abrasive nature of oxidized coproporphyrin III causes chronic chemical cholangitis (inflammation of the bile ducts). Over decades, this relentless inflammatory turnover dramatically increases the risk of malignant transformation, culminating in cholangiocarcinoma.
- **Cutaneous Lymphoproliferation:** Porphyrins deposited in the dermis are further photo-activated by ultraviolet light, generating immense local reactive oxygen species (ROS). This causes immediate symptoms (photosensitivity, blistering, pruritus) and acts as a source of chronic antigenic stimulation.

This constant state of immunological hyper-vigilance in the skin serves as a potent trigger for the development of primary cutaneous marginal zone B-cell lymphomas (PCMZL).

4. Therapeutic Implications: Halting the Oxidative Cascade

Understanding SIBO and oncological risk in these patients as downstream consequences of an iron-catalyzed porphyrin oxidation completely shifts the therapeutic paradigm. Conventional treatments for SIBO (broad-spectrum antibiotics) or IBS (antispasmodics) only address the superficial symptoms without halting the continuous destruction of the enteric nervous system.

To achieve clinical remission and mitigate long-term oncological risk, treatment must target the two core pillars of the proposed mechanism: Fe²⁺-mediated oxidation and enterohepatic porphyrin recirculation.

4.1. Depleting the Oxidative Spark: Therapeutic Phlebotomy

While iron chelators might theoretically bind free iron, their inherent hepatotoxicity makes them contraindicated in a liver already stressed by porphyrin accumulation and potential cholangitis. Therefore, therapeutic phlebotomy emerges as the primary, highly effective intervention.

Phlebotomy achieves a dual clinical objective in this overlapping phenotype.

First, it mechanically removes the excess iron burden driven by the HFE mutation, drastically reducing the pool of reactive Fe²⁺ (NTBI) and halting the Fenton-mediated oxidation of coproporphyrinogen III.

Second, it reduces the total red blood cell mass.

By lowering hemoglobin levels, phlebotomy decreases the physiological demand for heme synthesis, effectively slowing down the enzymatic assembly line and reducing the massive accumulation of porphyrin precursors at the CPOX bottleneck.

4.2. Interrupting Enterohepatic Toxicity: Intestinal Sequestrants

Even with iron levels controlled, the liver continues to excrete previously accumulated oxidized porphyrins into the bile. Upon reaching the intestine, these rigid, toxic molecules cause local myenteric neuropathy and are subsequently reabsorbed into the bloodstream through enterohepatic circulation, perpetuating the systemic damage.

To physically remove these oxidized isomers from the gastrointestinal tract, the use of large, non-absorbable intestinal sequestrants could be interesting. Agents such as cholestyramine, activated charcoal, or chlorophyllin act as molecular sponges.

Because oxidized coproporphyrin III and these binders (particularly chlorophyllin) share similar planar, hydrophobic ring structures, they bind tightly together in the intestinal lumen through non-covalent hydrophobic interactions (pi-stacking).

By sequestering the toxic porphyrins, these binders prevent their reabsorption and facilitate their safe excretion in feces. This immediate clearance removes the chemical irritant from the intestinal walls, allowing the myenteric plexus to recover from the oxidative trauma. As autonomic nerve function is restored, normal gastrointestinal motility resumes, naturally resolving the stagnant environment that allowed SIBO to flourish in the first place.

4.3. Upstream Enzymatic Silencing in Refractory Cases

In highly complex or refractory cases where iron depletion (phlebotomy) and intestinal sequestration are insufficient to halt the neurovisceral and inflammatory progression, upstream pharmacological intervention would be necessary.

In these severe scenarios, the application of RNA interference (RNAi) therapies, such as Givosiran—a small interfering RNA (siRNA) directed against delta-aminolevulinic acid synthase 1 (ALAS1)—offers a definitive genetic off-switch.

By silencing ALAS1 messenger RNA in the liver, this therapy profoundly downregulates the first and rate-limiting step of hepatic heme biosynthesis. This upstream blockade effectively shuts down the pathway long before the CPOX bottleneck is reached, completely preventing the initial accumulation of coproporphyrinogen III.

By starving the oxidative Fenton cycle of its primary porphyrin substrate, RNAi therapy halts the production of the neurotoxic and oncogenic oxidized isomers at their source, providing a critical lifeline for patients facing severe autonomic failure or high malignant risk.

5. Conclusion

The convergence of Hereditary **Coproporphyrinuria** and HFE-mediated iron overload represents a devastating synergistic metabolic failure.

This conceptual model reframes refractory SIBO, severe functional gastrointestinal disorders, and specific oncological risks (such as cholangiocarcinoma and cutaneous lymphomas) not as

idiopathic or isolated diseases, but as the direct downstream consequences of localized, **iron-catalyzed porphyrin toxicity**.

By identifying free ferrous iron (Fe²⁺) as the primary oxidative spark that transforms inert coproporphyrinogen III into a rigid, neurotoxic, and highly inflammatory molecule, we uncover a crucial therapeutic window.

The clinical management of these complex, overlapping phenotypes must pivot from mere symptomatic suppression, such as endless cycles of broad-spectrum antibiotics for SIBO, toward targeted metabolic disruption.

Interventions such as therapeutic phlebotomy to deplete the oxidative catalyst and reduce heme demand, intestinal sequestrants to break the enterohepatic toxic loop, and targeted RNAi therapies (like Givosiran) to silence upstream precursor production, offer a definitive, mechanism-based approach.

Ultimately, this framework underscores the absolute necessity of multidisciplinary medical evaluation.

In patients presenting with a complex matrix of intractable neurogastrointestinal dysmotility (SIBO/IBS), cardiac arrhythmias, postural instability, unexplained arthralgia (particularly in the upper extremities), and active cutaneous manifestations, such as photosensitivity, impaired wound healing, and ferritin-correlated pruritus, physicians must look beyond localized symptomatic treatments.

Faced with this multisystemic presentation, it is clinically urgent to investigate the intersection of heme biosynthesis and iron metabolism.

References

1. Bissell, D. M., Anderson, K. E., & Bonkovsky, H. L. (2017). Porphyria. *New England Journal of Medicine*, 377(9), 862-872. <https://doi.org/10.1056/NEJMra1608634>
2. Brissot, P., Ropert, M., Le Lan, C., & Loréal, O. (2012). Non-transferrin bound iron: A key role in iron overload and iron toxicity. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1820(3), 403-410. <https://doi.org/10.1016/j.bbagen.2011.07.014>
3. Pietrangelo, A. (2010). Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. *Gastroenterology*, 139(2), 393-408. <https://doi.org/10.1053/j.gastro.2010.06.013>
4. Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. *The American Journal of Gastroenterology*, 115(2), 165-178. <https://doi.org/10.14309/ajg.0000000000000501>
5. Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., ... & Anderson, K. E. (2020). Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyrin. *New England Journal of Medicine*, 382(24), 2289-2301. <https://doi.org/10.1056/NEJMoa1913147>
6. Winterbourn, C. C. (1995). Toxicity of iron and hydrogen peroxide: the Fenton reaction. *Toxicology Letters*, 82, 969-974. [https://doi.org/10.1016/0378-4274\(95\)03532-X](https://doi.org/10.1016/0378-4274(95)03532-X)

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.